RecruitingAtopic Dermatitis
Mechanisms of Increased Disease Severity in AD Patients With the IL-4Ra R576 Polymorphism
Eligible age
6–65 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This protocol is primarily looking to see if the IL-4Ra R576 polymorphism is associated with increased clinical, immunological and microbial markers of disease activity in patients with Atopic dermatitis.
Sponsor: Boston Children's Hospital
You may qualify if…
- ✓ 1. Male or female participants ≥6 to 65 yrs of age
- ✓ 2. Meet AD Standard Diagnostic Criteria
You may not qualify if…
- ✕ 1. Enrollment in another clinical trial
- ✕ 2. Hypersensitivity to an agent used for the skin decolonization protocol
- ✕ 3. Use within 4 weeks of systemic treatment with immunosuppressive/immunomodulating drugs (corticosteroids, cyclosporine, mycophenolate, JAK inhibitors, azathioprine, methotrexate)
- ✕ 4. Phototherapy for AD within 4 weeks
- ✕ 5. Treatment with biologics (dupilumab, omalizumab, benralizumab, etc) within sixteen weeks
- ✕ 6. Use of topical steroids, topical calcineurin inhibitors or crisaborale within 7 days
- ✕ 7. Bleach baths within 7 days of the first Visit
- ✕ 8. Use of oral or topical antibiotics within 21 days of the beginning of the study
Where it's recruiting
Massachusetts
Boston
Source: ClinicalTrials.gov · NCT04455906 · last updated 2026-05-18